PUFA in the pathogenesis and treatment of patients with multiple sclerosis

Proceedings of the Nutrition Society

Volumn 67, Issue OCE, 2008, Pages

  Harbige, L S ^a,b   Pinto, E ^a   Xiang, M ^a   Leach, M ^a,b   Sharief, M K ^c  

^a UNIVERSITY OF GREENWICH   (United Kingdom)

^b MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPIC ACID; ARACHIDONIC ACID; BGC 20 884; FATTY ACID; GAMMA LINOLENIC ACID; INTERLEUKIN 1BETA; LINOLENIC ACID; OMEGA 6 FATTY ACID; PLACEBO; POLYETHYLENEGLYCOL ADIPATE; POLYUNSATURATED FATTY ACID; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

CELL ISOLATION; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; EXPANDED DISABILITY STATUS SCALE; HUMAN; HUMAN CELL; LOW DRUG DOSE; MULTIPLE SCLEROSIS; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; RELAPSE; TREATMENT OUTCOME;

EID: 47249099367     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S0029665108006307     Document Type: Conference Paper

References (2)

1. Hollifield, R, Harbige L, Pham-Dinh D & Sharief MK (2003) Autoimmunity 36, 133-144.
2. Harbige L, Layward M, Morris-Downes M, Dumonde D & Amor A (2000) Clin Exp Immunol 122, 445-452.